摘要
目的探讨心通口服液联合曲美他嗪应用于冠心病心绞痛患者治疗中对临床疗效、心室重构及炎性因子水平的影响。方法方便选取2020年3月—2021年3月该院收治的冠心病心绞痛患者92例作为研究对象,按照随机摸球法分成观察组(n=46)与对照组(n=46),对照组采用曲美他嗪治疗,观察组采用心通口服液联合曲美他嗪治疗,对两组临床疗效、心室重构、炎性因子水平、血管内皮功能、心绞痛发作情况进行比较。结果观察组治疗总有效率较对照组更高,差异有统计学意义(P<0.05);治疗后两组左心室射血分数(LVEF)提高,左心室收缩末期容积(LVESV)、左心室舒张末期容积(LVEDV)降低,观察组LVEF较对照组更高,LVESV、LVEDV更低,差异有统计学意义(P<0.05);治疗后两组炎性因子水平降低,观察组水平较对照组更低,差异有统计学意义(P<0.05);治疗后两组肱动脉介导内皮依赖性舒张功能(FMD)、一氧化氮(NO)明显提高,浆内皮素(ET-1)明显降低,观察组FMD、NO较对照组更高,ET-1更低,差异有统计学意义(P<0.05);治疗后两组心绞痛发作时间缩短,发作次数减少,观察组心绞痛发作时间(3.96±1.48)min/次较对照组(5.73±1.56)min/次更短,发作次数(3.54±1.02)次/周较对照组(5.59±1.24)次/周更少,差异有统计学意义(t=5.583、8.659,P<0.05)。结论心通口服液联合曲美他嗪应用于冠心病心绞痛患者治疗中,可提高临床疗效,改善炎性因子水平、心室重构及心绞痛发作情况,增强血管内皮功能。
Objective To investigate the effect of Xintong Oral Liquid combined with trimetazidine on the clinical efficacy,ventricular remodeling and inflammatory factor levels in the treatment of patients with coronary heart disease and angina pectoris.Methods 92 patients with coronary heart disease and angina pectoris admitted to the hospital from March 2020 to March 2021 were conveniently selected as the research subjects.According to the random touch ball method,they were divided into observation group(n=46)and control group(n=46).The control group was treated with trimetazidine,and the observation group was treated with Xintong oral liquid combined with trimetazidine.The clinical efficacy,ventricular remodeling,inflammatory factor levels,vascular endothelial function,and angina pectoris were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,left ventricular ejection fraction(LVEF)was increased and left ventricular end systolic volume(LVESV)and left ventricular end diastolic volume(LVEDV)were decreased in the two groups.LVEF in the observation group was higher than that in the control group,while LVESV and LVEDV were lower,the differences were statistically significant(P<0.05).After treatment,the levels of inflammatory factors in the two groups decreased,and the level in the observation group was lower than that in the control group,the difference was statistically significant(P<0.05).After treatment,the humeral artery mediated endothelium-dependent relaxation function(FMD)and nitric oxide(NO)were significantly increased,and plasma endothelin(ET-1)was significantly decreased in the two groups,FMD and NO in the observation group were higher than those in the control group,while ET-1 was lower,the differences were statistically significant(P<0.05);after treatment,the time of angina pectoris in the two groups was shortened,and the number of attacks decreased,the attack time of angina pectoris in the observation group(3.96±1.48)min/times was shorter than that in the control group(5.73±1.56)min/times,and the number of attacks was(3.54±1.02)times/week compared with the control group(5.59±1.24)times/week,the difference was statistically significant(t=5.583,8.659,P<0.05).Conclusion Xintong Oral Liquid combined with trimetazidine in the treatment of patients with coronary heart disease and angina pectoris can improve the clinical efficacy,improve the level of inflammatory factors,ventricular remodeling and angina pectoris,and enhance vascular endothelial function.
作者
李玉香
LI Yuxiang(Second Department of Cardiology,Xintai People's Hospital,Tai'an,Shandong Province,271200 China)
出处
《中外医疗》
2022年第10期18-22,共5页
China & Foreign Medical Treatment
关键词
心通口服液
曲美他嗪
冠心病心绞痛
临床疗效
心室重构
炎性因子
Xintong oral liquid
Trimetazidine
Coronary heart disease and angina pectoris
Clinical efficacy
Ventricular remodeling
Inflammatory factors
